Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

Bill Sibold, Madrigal Pharmaceuticals CEO May 11, 2026 02:27 PM EDT PharmaMarketing Rezd­if­fra is ex­ceed­ing Wall Street's ex­pec­ta­tions as the MASH mar­ket takes shape Nicole DeFeudis Senior Reporter It seems there’s room for two in the MASH mar­ket. When No­vo Nordisk’s block­buster weight loss drug We­govy won ap­proval in Au­gust 2025 to treat … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER